Page 86 - Read Online

Osho et al. Hepatoma Res 2020;6:55 I http://dx.doi.org/10.20517/2394-5079.2020.42 Page 15 of 15

hepatocellular carcinoma. N Engl J Med 2018;379:54-63.
95. Bruix J, Qin S, Merle P, Granito A, Huang Y, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib
treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
96. Kudo M, Finn RS, Qin S, Han K, Ikeda K, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable
hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73.
97. Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, et al. Comparison of tumor response by response evaluation criteria in solid
tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012;118:147-56.
98. Kudo M, Finn RS, Qin S, Han K, Ikeda K, et al. Analysis of survival and objective response (OR) in patients with hepatocellular
carcinoma in a phase III study of lenvatinib (REFLECT). JCO 2019;37:186.
99. Llovet JM, Montal R, Villanueva A. Randomized trials and endpoints in advanced HCC: role of PFS as a surrogate of survival. J Hepatol
2019;70:1262-77.
100. Bangaru S, Marrero JA, Singal AG. Review article: new therapeutic interventions for advanced hepatocellular carcinoma. Aliment
Pharmacol Ther 2020;51:78-89.
101. El-khoueiry AB, Melero I, Yau TC, Crocenzi TS, Kudo M, et al. Impact of antitumor activity on survival outcomes, and nonconventional
benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040. JCO
2018;36:475.
102. Grierson P, Crites D, Ruzinova MB, Yano M, Lim KH. Distinct clinical and magnetic resonance features of metastatic hepatocellular
carcinoma treated with pembrolizumab: a case report of late response after pseudoprogression. Hepatol Commun 2018;2:148-51.
103. Wong DJ, Lee J, Choo SP, Thng CH, Hennedige T. Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint
inhibitor use: a case series. Immunotherapy 2019;11:167-75.
104. Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, et al. iRECIST: guidelines for response criteria for use in trials testing
immunotherapeutics. Lancet Oncol 2017;18:e143-52.
105. Henze J, Maintz D, Persigehl T. RECIST 1.1, irRECIST 1.1, and mRECIST: how to do. Curr Radiol Rep 2016;4.
106. Edeline J, Karwal M, Zhu AX, Finn RS, Cattan S, et al. RECIST v1.1 and irRECIST outcomes in advanced HCC treated with
pembrolizumab (pembro). JCO 2020;38:528.
107. Zwanenburg A, Vallières M, Abdalah MA, Aerts HJWL, Andrearczyk V, et al. The image biomarker standardization initiative:
standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology 2020;295:328-38.
108. Kim Y, Furlan A, Borhani AA, Bae KT. Computer-aided diagnosis program for classifying the risk of hepatocellular carcinoma on MR
images following liver imaging reporting and data system (LI-RADS). J Magn Reson Imaging 2018;47:710-22.
109. Hectors SJ, Lewis S, Besa C, King MJ, Said D, et al. MRI radiomics features predict immuno-oncological characteristics of hepatocellular
carcinoma. Eur Radiol 2020;30:3759-69.